Jos H. Beijnen

发表

ADME‐Enabling Technologies in Drug Design and Development. Edited by Donglu Zhang and Sekhar Surapaneni

Jos H. Beijnen, J. Beijnen, 2013 .

Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM

Jos H. Beijnen, Ron J. Keizer, Michel van Benten, 2011, Comput. Methods Programs Biomed..

Comparison of normalisation methods for surface-enhanced laser desorption and ionisation (SELDI) time-of-flight (TOF) mass spectrometry data

Marcel J. T. Reinders, Lodewyk F. A. Wessels, Wouter Meuleman, 2008, BMC Bioinformatics.

Dataset for: The G2 checkpoint: a node-based molecular switch

Wiley Admin, Jos H. Beijnen, Thomas Wurdinger, 2017 .

The Effect of Low pH on Breast Cancer Resistance Protein (ABCG2)-Mediated Transport of Methotrexate, 7-Hydroxymethotrexate, Methotrexate Diglutamate, Folic Acid, Mitoxantrone, Topotecan, and Resveratrol in In Vitro Drug Transport Models

Jos H. Beijnen, Piet Borst, Gerrit Jansen, 2007, Molecular Pharmacology.

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080

Mats O. Karlsson, Jos H. Beijnen, Ron J. Keizer, 2010, Journal of Pharmacokinetics and Pharmacodynamics.

Monitoring Carboplatin Concentrations in Saliva: A Replacement for Plasma Ultrafiltrate Measurements?

Jos H. Beijnen, Olaf van Tellingen, Laurence J. C. van Warmerdam, 1995, Therapeutic drug monitoring.

Bcrp1;Mdr1a/b;Mrp2 Combination Knockout Mice: Altered Disposition of the Dietary Carcinogen PhIP (2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine) and Its Genotoxic Metabolites

Tom F. A. de Greef, Jos H. Beijnen, Luc Brunsveld, 2014, Molecular Pharmacology.

Clinical proteomics in breast cancer: a review

Jos H. Beijnen, Marie-Christine W. Gast, J. Schellens, 2009, Breast Cancer Research and Treatment.

Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment

Jos H. Beijnen, Alfred H. Schinkel, H. Rosing, 2009, Clinical Cancer Research.

Cyclodextrins in the Pharmaceutical Field

Jos H. Beijnen, Auke Bult, J. Beijnen, 1991 .

In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2

Jos H. Beijnen, Alfred H. Schinkel, J. Schellens, 2007, Molecular Cancer Therapeutics.

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential

Evert Bosdriesz, Jos H. Beijnen, Ji-Ying Song, 2018, Cell.

BIOANALYTICAL LIQUID CHROMATOGRAPHIC METHOD VALIDATION. A REVIEW OF CURRENT PRACTICES AND PROCEDURES

Jos H. Beijnen, A. Bult, H. Rosing, 2000 .

Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation

Jos H. Beijnen, Alfred H. Schinkel, J. Beijnen, 2010, Molecular Cancer Therapeutics.

Treatment Individualization in Colorectal Cancer

Jos H. Beijnen, René Bernards, R. Bernards, 2015, Current Colorectal Cancer Reports.

New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′-difluorodeoxyuridine

Jos H. Beijnen, Jashvant D. Unadkat, J. Schellens, 2008, Molecular Cancer Therapeutics.

P-Glycoprotein Limits Oral Availability, Brain Penetration, and Toxicity of an Anionic Drug, the Antibiotic Salinomycin

Jos H. Beijnen, Alfred H. Schinkel, J. Beijnen, 2007, Antimicrobial Agents and Chemotherapy.

A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine

Jos H. Beijnen, J. Schellens, H. Rosing, 2016, Cancer Chemotherapy and Pharmacology.

Predictive Value of Microdose Pharmacokinetics

Jos H. Beijnen, Alwin D. R. Huitema, H. Rosing, 2019, Clinical Pharmacokinetics.

Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure

Willem Boogerd, Jos H. Beijnen, J. Schellens, 2001, Cancer Chemotherapy and Pharmacology.

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

Jos H. Beijnen, Ron J. Keizer, Alwin D. R. Huitema, 2010, Clinical pharmacokinetics.

Individualised Cancer Chemotherapy: Strategies and Performance of Prospective Studies on Therapeutic Drug Monitoring with Dose Adaptation

Jos H. Beijnen, Alwin D. R. Huitema, S. Rodenhuis, 2005, Clinical pharmacokinetics.

Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein

Jos H. Beijnen, Piet Borst, Jan Wijnholds, 1997, Nature Medicine.

A Mechanism-Based Pharmacokinetic Model for the Cytochrome P450 Drug–Drug Interaction between Cyclophosphamide and ThioTEPA and the Autoinduction of Cyclophosphamide

Jos H. Beijnen, Alwin D. R. Huitema, S. Rodenhuis, 2001, Journal of Pharmacokinetics and Pharmacodynamics.